Fax: (011) 49-241-8082481
Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults
Preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG
Article first published online: 22 FEB 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 19, pages 4892–4900, 1 October 2012
How to Cite
Buehrlen, M., Zwaan, C. M., Granzen, B., Lassay, L., Deutz, P., Vorwerk, P., Staatz, G., Gademann, G., Christiansen, H., Oldenburger, F., Tamm, M. and Mertens, R. (2012), Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults. Cancer, 118: 4892–4900. doi: 10.1002/cncr.27395
- Issue published online: 19 SEP 2012
- Article first published online: 22 FEB 2012
- Manuscript Accepted: 18 NOV 2011
- Manuscript Revised: 10 NOV 2011
- Manuscript Received: 26 AUG 2011
- nasopharyngeal carcinoma;
- interferon beta;
- positron emission tomography scan
The authors report preliminary results from a prospective multicenter study (Nasopharyngeal Carcinoma [NPC] 2003 German Society of Pediatric Oncology and Hematology/German Children's Oncology Group [NPC-2003-GPOH/DCOG]).
From 2003 to 2010, 45 patients (ages 8-20 years), including 1 patient with stage II NPC and 44 patients with stage III/IV NPC, were recruited to the study. The patient with stage II disease received radiotherapy (59.4 grays [Gy]). The patients with stage III/IV disease received 3 courses of neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and folinic acid. The cumulative irradiation dose was 54 Gy in 5 patients, who achieved complete remission after neoadjuvant chemotherapy, and 59.4 Gy in the remaining 40 patients. All patients received concomitant cisplatin during the first week and last week of irradiation. After irradiation, all patients received interferon beta for 6 months. Tumor response was evaluated by magnetic resonance imaging studies and positron emission tomography scans.
After the completion of treatment, 43 of 45 patients were in complete remission. In 2 patients, only a partial response was achieved, followed by distant metastases (1 patient) or local progression and distant metastases (1 patient), 6 months and 10 months after diagnosis, respectively. Another patient developed a solitary pelvic bone metastasis 21 months after diagnosis. After a median follow-up of 30 months (range, 6-95 months), the event-free survival rate was 92.4%, and the overall survival was 97.1%. Acute toxicity consisted mainly of leucopenia, mucositis, and nausea; and late toxicity consisted of hearing loss and hypothyroidism.
Combined therapy with neoadjuvant chemotherapy, radiochemotherapy, and interferon beta was well tolerated and resulted in a very good outcome that was superior to the outcomes of published results from all other pediatric NPC study groups. Cancer 2012. © 2012 American Cancer Society.